Fig. 2From: Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndromeMeans (with standard deviation error bars) for the primary outcome measures as a function of the treatment group. Note that all comparisons are significant (p < .05) after controlling for pre-treatment valuesBack to article page